Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype

Author:

Poiré Xavier1ORCID,Labopin Myriam2ORCID,Polge Emmanuelle3,Ganser Arnold4,Socie Gerard5ORCID,Gedde-Dahl Tobias,Forcade Edouard6ORCID,Finke Jürgen7,Chalandon Yves8ORCID,BULABOIS Claude-Eric9,Yakoub-Agha Ibrahim,Aljurf Mahmoud D10ORCID,Kroeger Nicolaus11ORCID,Blau Igor-Wolfgang12,Nagler Arnon13ORCID,Esteve Jordi14ORCID,Mohty Mohamad15ORCID

Affiliation:

1. Cliniques Universitaires St-Luc

2. Hôpital Saint-Antoine

3. Acute Leukemia Working Party, European Society for Blood and Marrow Transplantation Paris Study Office/European Center for Biostatistical and Epidemiological Evaluation in Hematopoietic Cell Therapy

4. Hannover Medical School

5. Assistance Publique des Hopitaux de Paris, Saint Louis hospital

6. Bordeaux University Hospital

7. Universitätsklinikum Freidburg

8. Hôpitaux Universitaire de Genève

9. Université Grenoble Alpes

10. King Faisal Specialist Hospital & Research Center

11. University Medical Center Hamburg-Eppendorf (UKE)

12. Department of Hematology, Oncology and Tumorimmunology, Charite University School of Medicine, Berlin, Germany

13. Chaim Sheba Medical Center

14. Hospital Clínic of Barcelona

15. Hôpital St Antoine, Sorbonne University, INSERM UMRs 938

Abstract

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML. A total of 236 patients were identified within the EBMT registry as having HDK comprising 95 pure (pHDK) and 141 with other cytogenetic abnormalities (HDK+). The 2-year probability of leukemia-free survival (LFS) was 50% for pHDK and 31% for HDK+ (p=0.003). The 2-year probability of overall survival (OS) was 57% for pHDK and 36% for HDK+ (p=0.007). The 2-year cumulative incidence of relapse (RI) was 22% for pHDK and 44% for HDK+ (p=0.001). The 2-year probability of graft-versus-host disease (GvHD)-free and relapse-free survival (GRFS) was 36% for pHDK and 21% for HDK+ (p=0.01). On multivariate analysis, pHDK remained associated with significantly better LFS, OS and GRFS and lower RI (all p-values<0.004). pHDK AML constitutes probably a distinct cytogenetic entity from HDK+ or other non-hyperdiploid CK AML with better outcomes after allo-HCT.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3